SCHEMBL2474399

SCHEMBL2474399

COc1ccc(C(c2ccccc2)(c2ccccc2)C(c2ccccc2)(c2ccccc2)c2cccc3ccccc23)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.45
NPC1 O15118 2/20 0.43
KMT2A Q03164 2/20 0.43
KIF11 P52732 2/20 0.41
KCNH2 Q12809 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
CA4 P22748 1/20 0.39
LMNA P02545 1/20 0.39
KCNJ11 Q14654 1/20 0.39
LTA4H P09960 1/20 0.39
POLB P06746 2/20 0.39
MAPT P10636 1/20 0.39
CYP1A2 P05177 2/20 0.38
CYP1A1 P04798 1/20 0.38
CYP1B1 Q16678 1/20 0.38
CYP2A6 P11509 1/20 0.38
KDM1A O60341 1/20 0.38
RAD52 P43351 1/20 0.38
GFER P55789 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2187746 0.85 HSD17B10 (0.43) KIF11TDP1CYP1A2CYP1B1CYP2A6
SCHEMBL1286989 0.81 CA4 (0.59) RAB9ANPC1KIF11KCNH2CA4
SCHEMBL8648265 0.81 CA4 (0.59) RAB9ANPC1KIF11KCNH2CA4
SCHEMBL8858901 0.81 CA4 (0.59) RAB9ANPC1KIF11KCNH2CA4
SCHEMBL14856630 0.81 CA4 (0.59) RAB9ANPC1KIF11KCNH2CA4
SCHEMBL5051055 0.81 CA4 (0.59) RAB9ANPC1KIF11KCNH2CA4
SCHEMBL4191295 0.78 RAB9A (0.45) RAB9ANPC1KMT2AL3MBTL1TDP1
SCHEMBL19149263 0.78 KMT2A (0.47) RAB9ANPC1KMT2AL3MBTL1TDP1
SCHEMBL17295935 0.78 KMT2A (0.47) RAB9ANPC1KMT2AL3MBTL1TDP1
SCHEMBL16549994 0.75 KMT2A (0.44) RAB9ANPC1KMT2AL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024145435-A2 LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS Life Technologies Corporation (US) 2024-07-04 WO disclosed
WO-2023067132-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2023-04-27 WO disclosed
EP-3865135-A2 NEUROACTIVE STEROIDS FOR USE IN THERAPY Sage Therapeutics, Inc. (US) 2021-08-18 EP disclosed
US-10406237-B2 Amine-containing transfection reagents and methods for making and using same LIFE TECHNOLOLGIES CORPORATION (US) 2019-09-10 US disclosed
EP-3470395-A1 AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME Life Technologies Corporation (US) 2019-04-17 EP disclosed
EP-2640700-B1 AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME LIFE TECHNOLOGIES CORP (US) 2018-10-31 EP disclosed
US-20180200374-A1 AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME Life Technologies Corporation 2018-07-19 US disclosed
US-9901642-B2 Amine-containing transfection reagents and methods for making and using same Life Technologies Corporation (US) 2018-02-27 US disclosed
EP-3183262-A1 NOVEL GLYCAN CONJUGATES AND USE THEREOF Academia Sinica (TW) 2017-06-28 EP disclosed
WO-2016029071-A1 NOVEL GLYCAN CONJUGATES AND USE THEREOF ACADEMIA SINICA (TW) 2016-02-25 WO disclosed
EP-2370436-A1 AZAQUINOLINONE DERIVATIVES AND USES THEREOF Link Medicine Corporation (US) 2011-10-05 EP disclosed
EP-2244694-A2 THERAPEUTIC COMPOSITIONS COMPRISING AN AMINE-CONTAINING LIPID AND A PROTEIN Shire Human Genetic Therapies, Inc. (US) 2010-11-03 EP disclosed
WO-2010057006-A9 AZAQUINOLINONE DERIVATIVES AND USES THEREOF LINK MEDICINE CORPORATION (US) 2010-09-16 WO disclosed
WO-2010057006-A1 AZAQUINOLINONE DERIVATIVES AND USES THEREOF LINK MEDICINE CORPORATION (US) 2010-05-20 WO disclosed
WO-2009097332-A2 THERAPEUTIC COMPOSITIONS SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2009-08-06 WO disclosed
EP-1912679-A4 AMINE-CONTAINING LIPIDS AND USES THEREOF MASSACHUSETTS INST TECHNOLOGY (US) 2009-07-29 EP disclosed
WO-2008144514-A2 POLYOL-BASED POLYMERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2008-11-27 WO disclosed
EP-1912679-A2 AMINE-CONTAINING LIPIDS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2008-04-23 EP disclosed
EP-1849760-A1 Ether compounds, compositions, and uses thereof Esperion Therapeutics Inc. (US) 2007-10-31 EP disclosed
WO-2006138380-A2 AMINE-CONTAINING LIPIDS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10406237-B2 Amine-containing transfection reagents and methods for making and using same SNRPA, NUDT21, SOAT2 RAB9A 3132/4885NPC1 87/4885KMT2A 908/4885
US-20180200374-A1 AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME SNRPA, NUDT21, SOAT2 RAB9A 3132/4885NPC1 87/4885KMT2A 908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.